Recurrent Malignant Glioma Market

Market Overview:

The 7 major recurrent malignant glioma markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.

The recurrent malignant glioma market has been comprehensively analyzed in IMARC's new report titled "Recurrent Malignant Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Recurrent malignant glioma is a devastating form of brain cancer characterized by the regrowth of malignant glial cells within the brain tissue. These cells provide support and protection to neurons, and when they become cancerous, they give rise to gliomas. This aggressive condition predominantly includes glioblastomas, anaplastic astrocytoma, and other high-grade gliomas. The symptoms of the ailment can differ depending on the size and location of the tumor. Some of the common manifestations include persistent headaches, seizures, cognitive decline, motor deficits, changes in personality or behavior, etc. These indications often overlap with those of the initial tumor presentation. The diagnosis of recurrent malignant glioma involves a combination of imaging techniques, notably magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, to visualize tumor growth and assess its extent. The healthcare provider will also perform a biopsy or surgical resection of the tumor tissue to confirm malignancy and determine the tumor's molecular characteristics, which can guide treatment decisions.

The escalating incidence of genetic anomalies affecting crucial signaling pathways, which create a supportive environment for tumor growth, is primarily driving the recurrent malignant glioma market. In addition to this, the inflating utilization of targeted therapies, like angiogenesis inhibitors, tyrosine kinase inhibitors, monoclonal antibodies, etc., to combat the aggressive nature of the cancer is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced surgical techniques, such as fluorescence-guided resection, which enhances precision and minimizes damage to surrounding healthy tissue, is further bolstering the market growth. Apart from this, the rising usage of tumor-treating fields therapy that disrupts cancer cell division through the application of low-intensity electric fields, is acting as another significant growth-inducing factor. This therapy mainly helps in impeding tumor progression and improving patient outcomes. Additionally, the emerging popularity of personalized medicines, since they are facilitated by genetic profiling and molecular diagnostics, thereby providing tailored strategies to combat the disease, is also augmenting the market growth. Furthermore, the increasing demand for immunotherapies, particularly checkpoint inhibitors and therapeutic vaccines, which work by harnessing the immune system's potential to target tumor cells, is expected to drive the recurrent malignant glioma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the recurrent malignant glioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for recurrent malignant glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the recurrent malignant glioma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the recurrent malignant glioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the recurrent malignant glioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current recurrent malignant glioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the recurrent malignant glioma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the recurrent malignant glioma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the recurrent malignant glioma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of recurrent malignant glioma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of recurrent malignant glioma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of recurrent malignant glioma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with recurrent malignant glioma across the seven major markets?
• What is the size of the recurrent malignant glioma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of recurrent malignant glioma?
• What will be the growth rate of patients across the seven major markets?
   

Recurrent Malignant Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for recurrent malignant glioma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the recurrent malignant glioma market?
• What are the key regulatory events related to the recurrent malignant glioma market?
• What is the structure of clinical trial landscape by status related to the recurrent malignant glioma market?
• What is the structure of clinical trial landscape by phase related to the recurrent malignant glioma market?
• What is the structure of clinical trial landscape by route of administration related to the recurrent malignant glioma market?